Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239200 · ClinicalTrials.gov registry record · Phase 2
Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00239200 is a Phase 2 study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 29 participants.
The verdict
NCT00239200, a Phase 2 study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is the determine whether a new compound, called lapatinib, can be effective in shrinking cancerous tumors of the esophagus that have recurred or spread somewhere else in the body. They also want to determine the toxicity of this regimen. Lapatinib blocks 2 receptors that sometimes are present on cancer cells (called epidermal growth factor receptor, and the Erb B2 receptor). It is possible that blocking these receptors may decrease the growth of the cancer cells.
Interventions
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00239200
The ClinicalTrials.gov registry entry for NCT00239200 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lapatinib is the first listed.
NCT00239200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00239200 about?
NCT00239200 is a clinical study titled "Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus". The purpose of this study is the determine whether a new compound, called lapatinib, can be effective in shrinking cancerous tumors of the esophagus that have recurred or spread somewhere else in the body. They also want to determine the toxicity of this regimen. Lapatinib blocks 2 receptors that so...
What is the current status of trial NCT00239200?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2005-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00239200?
The interventions under investigation include: Lapatinib (DRUG).
Who is sponsoring clinical trial NCT00239200?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.